Formycon has announced that its US filing for its FYB201 ranibizumab biosimilar has been delayed by several months, after the US Food and Drug Administration asked the firm and its licensing partner Bioeq for more information on the application following a manufacturing change.
Coherus BioSciences had recently struck a deal to acquire exclusive rights from Bioeq to commercialize the biosimilar rival to...






